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Summary 
Background & Aim: Fatigue is a debilitating symptom which frequently impairs the quality of life of 
patients with primary biliary cirrhosis (PBC), and which is unresponsive to currently available 
treatments. Although the mechanisms underpinning fatigue in PBC remain unclear there is an 
emerging consensus that CNS mechanisms play a key role. It has recently been shown that there 
is a strong association between abnormalities in sleep regulation, in particular excessive daytime 
somnolence, and fatigue severity in PBC. The CNS-acting drug modafinil has an established role 
in the treatment of excessive daytime somnolence in non-liver disease states. In this open label 
study we set out to explore the responses of PBC patients suffering from significant daytime 
somnolence and associated fatigue to modafinil therapy. 
Methods: All patients in the series (n=21) underwent daytime somnolence assessment using the 
Epworth Sleepiness Scale (ESS) and PBC symptom assessment using the PBC-40, a multi-
domain, disease specific, psychometrically robust quality of life measure. Modafinil was started at a 
dose of 100mg per day and was titrated according to tolerability and response. Patients underwent 
repeat ESS and PBC-40 assessment after 2 months of treatment. 
Results: Significant improvement was seen in ESS scores with Modafinil therapy (15.0 ± 3.3 v 8.0 
± 5.6, p<0.0005 (intention to treat (ITT) analysis)). An equally significant improvement in fatigue 
severity was also seen (PBC-40 Fatigue domain score (46.1 ± 6.2 v 33.5 ± 12.2, p<0.0001 (ITT 
analysis). 
Conclusions: Open label Modafinil therapy was associated, where tolerated by patients, with 
improvement in excessive daytime somnolence and associated fatigue in PBC. Further study in 
placebo-controlled trials is warranted.    
Background 
Primary biliary cirrhosis (PBC) is a chronic cholestatic liver disease (1). The condition, which 
affects up to 1 in 700 women over the age of 40 in some western European populations, is 
characterised by the development, in up to half of patients, of profound fatigue (2-5).  Studies 
performed both in PBC patients and in animal models of cholestasis have suggested that central 
nervous system processes, driven by a combination of cholestasis and inflammation, play a key 
role in the development of fatigue (6-8). Although our state of knowledge regarding potential 
mechanisms for the pathogenesis of fatigue in PBC has improved in recent years this has not, as 
yet, been reflected in significant improvements in the therapeutic options available for clinicians 
treating patients with this often disabling symptom (9).   
There is now emerging evidence to suggest that fatigue in PBC is associated with 
abnormality in sleep in general and with excessive daytime sleepiness in particular (2,10).  PBC 
patients sleep significantly more during the daytime than matched controls as assessed using both 
objective measures of sleep and subjective measures of perception of sleep (10). The degree of 
daytime sleep assessed using both approaches correlates both with general impairment of quality 
of life and with severity of fatigue. In light of the degree of daytime somnolence experienced by 
PBC patients, and the association between daytime somnolence and fatigue, we treated a series 
of PBC patients with excessive daytime somnolence with modafinil, a CNS-active agent effective 
for the treatment of daytime somnolence in the context of narcolepsy (11,12) and obstructive sleep 
apnea (13) and in excessive sleepiness in shift-work sleep disorder (14)). In a recent case series of 
5 PBC patients receiving modafinil therapy improvement in fatigue severity was reported, but not 
quantified(15). Here we report on the tolerability of modafinil in PBC patients and quantify its 
effects on daytime somnolence and fatigue in an open label study.  
 
 
Subjects & Methods 
Study Participants & Protocol 
The study participants were a series of 21 patients with definite or probable PBC, diagnosed using 
established criteria (16), who suffered from clinically significant daytime somnolence seen in our 
specialist PBC Service between September 2005 and February 2006. PBC patients were 
considered to be suitable for modafinil therapy if they had an Epworth Sleepiness Scale (ESS) 
score of 10 or greater in the absence of clinical features suggestive of obstructive sleep apnea. 
The ESS is a fully-validated and psychometrically robust tool for the assessment of daytime 
somnolence (17), which has previously been used in the assessment of excessive daytime 
somnolence in PBC patients (10). Clinically significant daytime somnolence is considered as being 
present when ESS scores exceed 10 (17).  Patients were excluded form modafinil therapy if they 
had a history of hypertension or other conditions recognised as contra-indicating modafinil therapy, 
had a history of, or features on investigation which were suggestive of, either other liver disease 
processes or inter-current conditions which are themselves associated with excessive daytime 
somnolence. Patients were also excluded form modafinil therapy if they were receiving other 
medications recognised as interacting with modafinil or which were associated with sleep 
disturbance. The clinical details of the patients in the series are outlined in Table 1.  None of the 
patients in this case series had advanced liver disease and none had clinical features suggestive 
of the presence of hepatic encephalopathy.  
All subjects underwent a full symptom assessment prior to commencement and after 2 
months of treatment. Patients underwent interim assessment after 4 weeks therapy at which issues 
relating to the tolerability of modafinil therapy were addressed and at the point of discontinuation of 
treatment in patients unable to tolerate modafinil. Assessment tools were the ESS and the PBC-40, 
a recently described disease specific health-related quality of life (HRQOL) measure developed 
and validated for use exclusively in PBC (18,19). The PBC-40 consists of 5 symptom domains 
relating to “fatigue”, “itch”, “cognitive” symptoms, “social and emotional” symptoms and “other 
symptoms”. The psychometric properties of the PBC-40 have been previously been described in 
detail (18). All patients were commenced on modafinil at a dose of 100mg per day. The dose was 
subsequently titrated according to both response and tolerability up to a maximum of 200mg/day.  
  
Statistical Analysis 
Symptom severity scores prior to treatment and at 2 months following the institution of treatment 
were compared using Student’s t-test on an “intention to treat” (ITT) and per protocol basis. 
Bonferroni’s correction was applied to correct for multiple testing of the domains of the PBC-40. 
Percentages of patients experiencing symptoms prior to therapy and at two months following the 
institution of therapy were compared using the Chi-squared test.  
Results 
All patients in the series initially received 100 mg per day of modafinil.  The dose was increased at 
one month of treatment to 200 mg according to tolerability and response. Patients unable to 
tolerate 100 mg initially halved the dose to 50 mg per day and, if still unable to tolerate it, 
discontinued treatment. Of the 21 participants, 14 were able to tolerate the treatment for the full 2 
month period. The mean dose amongst these recipients was 115 mg per day.  All 7 of the 
recipients who were unable to tolerate treatment suffered from significant headaches which 
resolved immediately on discontinuation of the treatment. In none of these patients was headache 
associated with significant increase in blood pressure. Amongst the patients not experiencing 
headaches and who took the drug for the full 2 months no other side-effects were identified.   
 Reduction was seen in degree of daytime somnolence (as assessed using the ESS) with 
modafinil treatment when analysed on both a per protocol basis (Figure 1) and on an intention to 
treat basis (mean ESS pre-treatment 15.0 ± 3.3 (possible value range 0-24) v post-treatment 7.9 ± 
5.6; p<0.0005). Of the 14 PBC patients able to tolerate modafinil 12 (86%) demonstrated 
improvement in their ESS score (range of improvement 18-94%). 11/14 (79%) of the patients able 
tolerate to modafinil (11/21 (52%) of the whole cohort) had a final ESS score of <10 (the 
established criterion for significant daytime somnolence and the ESS criterion for modafinil therapy 
in this series). 17 of the patients receiving modafinil in this series had severe fatigue at the outset 
of treatment (defined as a PBC-40 fatigue domain score >40) and the remaining 4 had moderate 
fatigue (PBC-40 fatigue domain score 29-39). Modafinil therapy was associated with a reduction in 
fatigue severity when analysed on both a per protocol basis (Figure 2, Table 2) and on an 
intention to treat basis (mean PBC-40 Fatigue domain score pre-treatment 46.1 ± 6.2 (possible 
value range 11-55) v post-treatment 33.5 ± 12.2; p<0.0001) (Table 2). Of the 11 patients able to 
tolerate modafinil who had severe fatigue at the outset of the study (the remaining 6 subjects with 
severe fatigue at study outset were unable to tolerate modafinil) only 1 still reported severe fatigue 
after 2 months of modafinil therapy (p=0.001). More modest, but still statistically significant 
improvement was seen in PBC-40 cognitive domain scores with Modafinil therapy when analysed 
on both a per protocol basis (Figure 3) and on an intention to treat basis (mean PBC-40 Cognitive 
domain pre-treatment 20.9 ± 4.7 (possible value range 6-30) v post-treatment 18.2 ± 5.3; 
p<0.0005) (Table 2). No significant improvement was seen in other PBC-40 domain scores 
following Modafinil therapy following correction for multiple testing. 
  
Discussion 
Recent studies have suggested that sleep disturbance is a significant problem in PBC, with 
patients being particularly troubled by excessive daytime somnolence (2,10). Modafinil is already 
widely, and effectively, used in the treatment of daytime somnolence in a number of disease 
settings including in narcolepsy. The first observation from this open label study is that Modafinil 
also appears, within the constraints of a study of this type, to be effective in the treatment of 
daytime somnolence in the PBC. The majority of patients who were able to tolerate the drug 
showed reduction in daytime somnolence. The degree of improvement seen in ESS was 
equivalent to that deemed to be clinically significant in other disease settings such as obstructive 
sleep apnea and narcolepsy. 
 Previous studies have demonstrated that, in addition to being an important factor in QOL 
impairment in its own right, daytime somnolence in PBC is strongly associated with the presence of 
the often life-altering fatigue that characterises this condition (10). Weaker associations are also 
seen with the other symptoms of the disease, including those associated with cognitive 
impairment. Given the strength of the association between daytime somnolence and fatigue in 
PBC we were interested in the extent to which Modafinil might also modulate other characteristic 
symptoms of PBC. We therefore examined the effects that modafinil had on the symptoms of PBC, 
including fatigue, assessed using the domain-based, disease-specific quality of life measure the 
PBC-40 (18). In keeping with our previous observations (10), the presence of excessive daytime 
somnolence in the current study cohort was again found, on pre-treatment assessment, to be 
associated with the presence of significant fatigue (10). Modafinil treatment was associated with 
improvement in PBC-40 fatigue domain scores in 86% of the series members who were able to 
tolerate it (57% of the whole cohort). The change in PBC-40 fatigue domain scores (ranging from 
18-94%) was markedly greater than the relatively low degree of natural variation in PBC-40 fatigue 
domain scores identified on repeat testing during the psychometric evaluation of the PBC-40 (18). 
The apparent effects of modafinil on fatigue in PBC patients identified in this case series extend 
the important earlier observations made by Kaplan & Bonis by increasing the numbers of patients 
treated, by quantifying the effect on fatigue, and by demonstrating a clear link with the effect of 
modafinil on daytime somnolence (15). The beneficial effect of modafinil on fatigue in PBC mirrors 
that seen in other disease states including narcolepsy (20), HIV infection (21), depression (22) and 
multiple sclerosis (23,24). 
  At present it is unclear whether any improvement in fatigue seen with modafinil is a specific 
or a non-specific effect. This reflects our current lack of understanding of the mechanisms whereby 
cholestasis, daytime somnolence, and fatigue are inter-related.  Further studies are required in this 
area. Studies on the mechanisms of action of modafinil have focused, in general, on direct CNS 
effects (25,26). Such a direct stimulatory effect is clearly a plausible mechanism for the effects on 
both sleep disturbance and fatigue in PBC. A potential alternative mechanism for the effects of 
modafinil on fatigue in PBC would, however, be via its effects on the autonomic nervous system 
and blood pressure regulation (26,27). Autonomic dysfunction, including hypotension and impaired 
blood pressure regulation, is a common feature in PBC patients and one which appears to 
associate with fatigue severity (28,29).   
In addition to the significant effect of modafinil therapy on fatigue a more modest 
improvement was seen with regard to symptoms of cognitive dysfunction in the modafinil treated 
PBC patients. This link between improvement in fatigue severity, improvement in severity of 
cognitive symptoms and reduction in daytime somnolence is in keeping with our earlier observation 
that PBC-40 Cognitive domain scores are associated with both PBC-40 Fatigue domain scores 
and ESS scores suggesting the presence of a linked aetiological process (10,19). It is interesting to 
note, in light of the apparent effects of modafinil on cognitive symptoms in PBC, that this agent was 
previously been demonstrated to objectively improve cognitive function in other sleep disturbance 
settings (30). Although slight improvement in other PBC-40 domain scores was seen with modafinil 
therapy none of the changes were statistically significant following correction for multiple testing.   
  Although this study has identified improvements in both daytime somnolence and fatigue in 
PBC following treatment with modafinil, and highlights the potential that this agent holds for the 
treatment of these difficult to manage symptoms of the disease, there are important outstanding 
aspects of the response which need to be addressed.  Firstly, and most importantly, these 
observations clearly need to be confirmed in a placebo-controlled trial. Previous experience of 
therapeutic agents offering promise for the treatment of fatigue in PBC has shown discrepancy 
between open label and subsequent placebo-controlled studies. A key issue will be the nature of 
the design of the definitive placebo-controlled trial.  Recent observations have suggested that the 
previously-used crossover protocol may not be appropriate for use in the PBC fatigue setting (31). 
A second important question will be the sustainability of any response to modafinil both in terms of 
daytime somnolence and of fatigue. Whereas no suggestion of tachyphalaxis was seen in this 
study the maximum length of time for which patients received the agent was only 2 months.  Given 
that fatigue appears to be a highly stable and none naturally resolving symptom in PBC the 
implication is that long term treatment will be necessary (32).  Appropriate consideration should be 
given to the pattern of dosing appropriate to give a long term sustained response.  A major 
limitation of many previous studies of symptom-directed therapy in PBC (particularly relating to the 
other characteristic symptom of itch) is that they have looked only at short term response to 
treatment and have failed to address the need for long term treatment with sustained safe function.   
In conclusion, this open label study would appear to support the previous observation that 
daytime somnolence is a significant factor in the expression of fatigue in PBC, and adds weight to 
early reports suggesting that modafinil reduces fatigue in PBC by replicating, extending and 
objectifying the findings. A placebo controlled trial in now warranted to confirm the effectiveness of 
this agent and to determine the extent to which side-effects, exemplified by headache may, as in 
other disease settings (33,34), limit its usefulness.  
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Tables 
Table 1: Clinical details of the series of patients receiving Modafinil 
Age (years) 56 [38-72] 
Female sex (%) 100 
Median [range] UDCA dose (mg) 600 [0-1200] 
Disease stage at last biopsy 
(Number of subjects with each stage 
early/advanced/No biopsy) 
7/1/13 
 
Bilirubin (µmol/l) median [range] 9 [5-19] 
Albumin (g/l) median [range] 40 [34-50] 
Alkaline phosphatase (IU/l) median [range] 110 [90-240] 
 
 
Table 2: Percentage improvement in PBC-40 domain scores seen with Modafanil therapy. 
Improvements that are statistically significant following correction for multiple testing are denoted in 
bold 
PBC-40 Domain Mean % Improvement  
(Intention to Treat Analysis) 
Mean % Improvement  
(Per-Protocol  Analysis) 
Fatigue 58 87 
Cognitive 20 30 
Itch 20 30 
Social & 
Emotional 
10 15 
Other Symptoms 8 12 
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Figure 1: Daytime somnolence in PBC patients prior to (pre), and 2 months after the institution of 
Modafinil (post) in patients able to tolerate Modafinil therapy.  
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Figure 2: PBC-40 Fatigue domain scores prior to (pre) and at 2 months following the institution of 
Modafinil (post) in patients able to tolerate Modafinil therapy 
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Figure 3: PBC-40 Cognitive domain scores prior to (pre) and at 2 months following the institution 
of Modafinil (post) in patients able to tolerate Modafinil therapy. 
 
